GlassScriptPhysician profile
Ha S Nguyen
NPI 1447275631
$6,779.37
in general payments reported to CMS, 2019-2025
29 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $450 · 2021: $1,595 · 2022: $1,198 · 2023: $345 · 2024: $861 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469 · Education: $5.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.96 |
| Education | $5.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,862.77 | 2019-2023 | |
| Ethicon US, LLC | $577.26 | 2020-2022 | |
| Pfizer INC. | $507.67 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $490.45 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $400.70 | 2021-2022 | |
| Therapeuticsmd, INC. | $395.28 | 2019-2021 | |
| Astellas Pharma US INC | $295.58 | 2024-2025 | Veozah |
| Sage Therapeutics, LLC | $291.81 | 2024-2025 | Zurzuvae |
| Medical Device Business Services, INC. | $255.42 | 2019-2022 | |
| Becton, Dickinson and Company | $187.58 | 2019 | |
| Hologic Sales and Service, LLC | $169.99 | 2019-2025 | Aptima, Novasure, Thinprep 2000 Processor |
| Aspira Women'S Health INC | $147.57 | 2022-2024 | Ova1 |
| Organon LLC | $132.55 | 2021-2023 | Nexplanon |
| Lilly USA, LLC | $125.82 | 2024-2025 | Zepbound, Mounjaro |
| Ucb, INC. | $125.01 | 2025 | Bimzelx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $122.03 | 2025 | |
| Novo Nordisk INC | $118.96 | 2025 | Ozempic |
| Biogen, INC. | $114.21 | 2025 | Zurzuvae |
| Inari Medical, INC. | $92.78 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Exeltis, USA INC. | $65.51 | 2023-2025 | Slynd |
| Roche Diagnostics Corporation | $58.27 | 2020-2021 | |
| Shield Therapeutics INC | $51.51 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $45.41 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $41.35 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.09 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.22 | 2024 | Rexulti, Abilify Asimtufii |
| Boston Scientific Corporation | $20.50 | 2020 | |
| Baxter Healthcare | $19.25 | 2024 | Perclot |
| Bayer Healthcare Pharmaceuticals INC. | $17.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ha Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.